Abdullah Karaer | Molecular Biology | Best Researcher Award

Posted on by sciencefather

Prof. Dr. Abdullah Karaer | Molecular Biology | Best Researcher Award 

Researcher, at Inonu University School of Medicine, Turkey.

Prof. Dr. Abdullah Karaer is a distinguished Turkish physician-scientist specializing in reproductive endocrinology and infertility. Born in 1977, he currently serves as Professor of Obstetrics & Gynecology at Inonu University, where he is also the Head of the IVF Unit and the Department of Obstetrics & Gynaecology. He founded and leads the Reproductive Sciences and Bioinformatics Research and Application Center at the same institution. With over two decades of experience, Dr. Karaer has contributed significantly to women’s health, fertility, and biomedical research. He integrates clinical expertise with advanced bioinformatics and omics technologies to tackle complex reproductive challenges. An active educator and mentor, he continues to shape the next generation of clinicians and scientists. His work has earned over 1000 citations, and his leadership in numerous interdisciplinary projects cements his role as a leading figure in reproductive medicine and academic innovation. 🌐🧪

Professional Profile

Scopus

ORCID

Google Scholar

🎓 Education 

Prof. Dr. Abdullah Karaer’s educational journey is a testament to his commitment to lifelong learning and interdisciplinary excellence. He earned his M.D. from Ankara University in 2001 and completed his specialization in Obstetrics & Gynaecology in 2007, defending a thesis on Y chromosome microdeletions in recurrent pregnancy loss. In 2022, he embarked on a PhD program in Stem Cells and Regenerative Medicine at Ankara University’s Stem Cell Institute, reflecting his interest in cutting-edge medical biotechnology. In 2024, he pursued an Associate’s degree in Computer Programming at Ankara University, signaling his commitment to bioinformatics and digital health. His solid grounding in clinical medicine, coupled with continuous academic development in genomics and informatics, uniquely positions him to lead translational research in reproductive sciences. 🧠📚💻

💼 Experience 

Dr. Karaer’s career spans clinical excellence, academic leadership, and pioneering research. Since 2018, he has served as Professor of Obstetrics & Gynecology at Inonu University, where he also leads the IVF Unit and the Division of Reproductive Endocrinology & Infertility. He founded the Reproductive Sciences and Bioinformatics Research and Application Center in 2019. Previously, he held roles as Associate Professor (2013–2018) and Assistant Professor (2010–2013) at the same university. His early clinical career includes posts at Merzifon Air Military Hospital and Siirt Women’s Health & Children Hospital. A dedicated educator, he mentors students at undergraduate and graduate levels, contributes to national medical education boards, and leads thesis supervision for future medical experts. His integration of patient care with translational research and data-driven solutions has set benchmarks in Turkey’s reproductive medicine landscape. 🏥📈👨‍🏫

🔬 Research Interest 

Prof. Karaer’s research is deeply rooted in reproductive sciences, with a focus on infertility, polycystic ovary syndrome (PCOS), endometriosis, oocyte quality, and assisted reproductive technologies. He harnesses multi-omics techniques—including metabolomics, transcriptomics, and metagenomics—to decode complex biological systems affecting fertility. His work examines the molecular underpinnings of follicular fluid composition, cumulus cell gene expression, and the impact of the vaginal microbiome on IVF outcomes. His interdisciplinary projects incorporate bioinformatics, proteomics, and advanced imaging, making his lab a hub for integrative reproductive biology. As a principal investigator in nationally and internationally funded studies, he collaborates on projects related to PCOS-related endometrial cancer, idiopathic male infertility, and placental pathophysiology in preeclampsia. Dr. Karaer’s innovative approach bridges bench-to-bedside research, aiming to enhance patient outcomes through precision reproductive medicine. 🧫🧬🧠

🏆 Awards 

Prof. Karaer’s career reflects a dedication to scientific excellence and public health impact. While formal award listings are not provided in this record, his leadership roles, continuous academic promotions, and invitations to lead national research projects attest to his recognition as an influential expert in reproductive medicine. He has served on national boards such as the National Medicine Specialty Board in Obstetrics & Gynecology and has been a key member of societies like the European Society of Human Reproduction and Embryology. His ongoing projects funded by TÜBİTAK, TÜSEB, and COST-EU illustrate the high level of trust and investment from both national and international scientific bodies. These honors underscore his capability to lead large-scale, multi-omics, and translational medical research projects addressing fertility and reproductive health. 🏅🌍📖

📚 Top Noted Publications

Dr. Karaer is the author of 65 scientific publications, cited over 1,095 times (Scopus) and 1,922 times (Google Scholar), with an h-index of 19 and 24 respectively. His studies appear in top-tier journals like BJOG, Andrology, Journal of Assisted Reproduction and Genetics, and Fertility and Sterility. His work spans vaginal microbiota, seminal and follicular fluid metabolomics, gene expression in cumulus cells, and endometriosis-related fertility outcomes. Notable publications include:

1. The Vaginal Microbiota Composition of Women Undergoing Assisted Reproduction

  • Journal: BJOG: An International Journal of Obstetrics & Gynaecology

  • Publication Year: 2021

  • Study Type: Prospective cohort study

  • Objective: To investigate the vaginal microbiota composition in women undergoing assisted reproduction and its potential impact on reproductive outcomes.

  • Key Findings: The study identified specific vaginal microbiota profiles associated with reproductive success, suggesting that certain microbial compositions may influence the outcomes of assisted reproductive technologies.

  • Link: PubMed Abstract

2. Metabolomics Analysis of Seminal Plasma in Patients with Idiopathic Oligoasthenoteratozoospermia Using High-Resolution NMR Spectroscopy

  • Journal: Andrology

  • Publication Year: 2020

  • Authors: A. Mumcu, A. Karaer, B. Dogan, G. Tuncay

  • Objective: To determine whether metabolites could serve as potential biomarkers for diagnosing male factor infertility by comparing seminal plasma samples from infertile men with oligoasthenoteratozoospermia (OAT) to those from normozoospermic controls.

  • Key Findings: The study found significant differences in metabolite levels between the two groups, with decreased levels of lactate, citrate, lysine, arginine, valine, glutamine, creatinine, α-ketoglutaric acid, spermine, and putrescine in OAT patients. Tyrosine levels were increased. The PLS-DA model achieved 89.29% sensitivity and 93.55% specificity in distinguishing between the groups.

  • Link: Wiley Online LibraryWiley Online Library

3. The Effect of Seminal Plasma Cadmium and Lead Levels on Semen Parameters in Male Subjects of Infertile Couples: A Prospective Cohort Study

  • Journal: Journal of Obstetrics and Gynaecology

  • Publication Year: 2020

  • Authors: Gorkem Tuncay, Abdullah Karaer, Emrullah Tanrikut, Onur Ozgul

  • Objective: To investigate the relationship between seminal plasma cadmium (Cd) and lead (Pb) levels and semen parameters in male partners of infertile couples.

  • Key Findings: Cadmium levels were significantly higher in men with hypospermia compared to those with normal semen volume (p = .049). No significant differences were observed in lead levels or other semen parameters. The findings suggest that environmental cadmium exposure may contribute to low semen volume.

  • Link: Taylor & Francis OnlineTaylor & Francis Online+1PubMed+1

4. Follicular Fluid Metabolomics in Maternal Aging

  • Journal: Journal of Assisted Reproduction and Genetics (JARG)

  • Publication Year: 2020

  • Objective: To analyze the metabolomic profile of follicular fluid in relation to maternal aging and its impact on oocyte quality and fertility.

  • Key Findings: The study identified age-related changes in the follicular fluid metabolome, suggesting that alterations in specific metabolites may affect oocyte competence and reproductive outcomes in older women.

  • Link: PubMed Abstract

5. Microarray Analysis in Endometriosis

  • Journal: Journal of Endometriosis and Pelvic Pain Disorders (JEPPD)

  • Publication Year: 2020

  • Objective: To utilize microarray analysis to identify gene expression patterns associated with endometriosis.

  • Key Findings: The study revealed specific gene expression profiles in endometrial tissues of patients with endometriosis, providing insights into the molecular mechanisms underlying the disease and potential targets for therapy.

  • Link: PubMed Abstract

Conclusion

Professor Abdullah Karaer is highly suitable for the Best Researcher Award. His multidisciplinary approach, consistent research productivity, leadership in reproductive and bioinformatics research, and proven mentorship make him a standout candidate. With minor enhancements in international engagement and digital presence, his profile would reach even greater global competitiveness.

Weiwei Fu | Molecular Biology | Best Researcher Award

Posted on by sciencefather

Dr. Weiwei Fu | Molecular Biology | Best Researcher Award 

Research assistant professor, at Peking University Third Hospital, China.

Dr. Fu Weiwei is an accomplished medical scientist specializing in gastroenterology and immunology. She currently serves as an Assistant Research Professor and Laboratory Director at the Gastroenterology Department, Peking University Third Hospital, where she leads research at the Beijing Key Laboratory. Dr. Fu earned her Ph.D. in Immunology from Peking University Health Science Center and has a strong foundation in traditional medicine, holding a Bachelor of Medicine from Shandong University. With more than a decade of experience in translational medical research, her work bridges cutting-edge immunological discoveries and practical clinical applications. Her focus lies in immune microenvironment dynamics, gastrointestinal tumor evolution, and the integration of traditional Chinese medicine for digestive disease therapies. She has delivered several high-profile international presentations and has published widely in leading scientific journals. Her contributions have significantly advanced the field of digestive immunology.

Professional Profile

Scopus

ORCID

🎓 Education

Dr. Fu’s academic journey began with a 5-year Bachelor of Medicine program at Shandong University of Traditional Chinese Medicine (2002–2007), where she laid a solid foundation in both conventional and traditional healthcare practices. Her early exposure to integrative medicine inspired a unique perspective on digestive health and immune response. Motivated by scientific rigor, she enrolled in the Combined Master’s and Ph.D. Program in Immunology (2008–2013) at Peking University Health Science Center, mentored by Prof. Wenling Han. This elite program sharpened her skills in molecular biology, immunopathology, and clinical translational research. Throughout her doctoral years, she focused on the host immune responses in cancer, particularly those related to gastric inflammation and tumorigenesis. This diverse academic training enables her to merge modern biomedical technologies with traditional insights, giving her an edge in the multidisciplinary field of digestive immunology.

🧪 Experience

Dr. Fu brings a wealth of research and clinical experience to her current position at the Gastroenterology Department, Peking University Third Hospital (2019–present), where she directs the Beijing Key Laboratory. As an Assistant Research Professor, she leads a team focusing on translational immunology in gastrointestinal diseases. Before this, she completed a prestigious postdoctoral fellowship (2013–2019) at the Tsinghua University Institute of Immunology under Prof. Chen Dong, an Academician of the Chinese Academy of Sciences. During this time, she worked on T-cell signaling, immune checkpoints, and the role of lymphoid cells in cancer. Her lab currently integrates clinical cohort data with multi-omics techniques to explore disease mechanisms. She is also instrumental in mentoring junior researchers and clinicians. Her work bridges laboratory immunology with bedside applications, ensuring scientific advancements are translated into improved diagnosis and therapy for patients.

🔬 Research Interests

Dr. Fu’s research centers on the immune microenvironment in gastrointestinal tumors and digestive tract diseases, such as gastric cancer and inflammatory bowel disease. She applies multi-omics technologies—including single-cell RNA sequencing, proteomics, and microbiome analysis—to decipher host-pathogen interactions and immune cell dynamics during disease evolution. A key aspect of her research is understanding how Helicobacter pylori infection initiates gastric lesions, tumor progression, and immune escape. She also investigates traditional Chinese medicine-based therapies, exploring their role in cancer prevention and immune modulation. Another focal point is early screening and biomarker discovery for precancerous lesions through clinical cohort studies. By integrating high-throughput data with clinical insights, her work aims to improve patient stratification and individualized treatments. Her interdisciplinary approach bridges immunology, oncology, and traditional medicine, placing her at the forefront of gastrointestinal research in China and beyond.

🏆 Awards

Dr. Fu’s scientific excellence has been consistently recognized. She won the Outstanding Paper Award at the 2023 Chinese Medical Association’s National Conference on Digestive Diseases (CGC 2023) for her oral presentation on immune profiling during colorectal cancer progression. Her continuous contributions to clinical immunology, translational oncology, and molecular diagnostics have earned her accolades from both national and international platforms. Her selection as an oral presenter at leading conferences—such as DDW 2024 in Washington, D.C., and UEGW 2023 in Copenhagen—speaks to her international recognition. She has also received patent grants for innovations in inflammation and cancer therapy, reflecting her drive for practical applications. As a dedicated researcher, educator, and innovator, Dr. Fu stands out as a top candidate for award nominations in the fields of biomedical research and clinical translational science.

📚 Top Noted Publications

Dr. Fu has authored and co-authored numerous impactful papers in top-tier journals (JCR Q1–Q3), often as first or corresponding author. Below are select publications with hyperlink.

2025

  1. Luteolin Improves Precancerous Gastric Mucosa by Binding STAT3
    International Journal of Biological Sciences (Q1, IF 8.1)
    📌 Co-Corresponding Author
    🧪 Original Research

  2. CMTM3 Regulates Colitis-Associated Cancer Progression
    Cellular and Molecular Gastroenterology and Hepatology (CMGH) (Q1, IF 7.1)
    📌 Co-Corresponding Author
    🧬 Original Research

  3. Cmtm4 Deficiency Exacerbates H. pylori-Induced Gastric Carcinogenesis
    Pathology International (Q2, IF 2.5)
    📌 Co-Corresponding Author
    🦠 Original Research

  4. The Host Immune Response Landscape in Gastric Cancer Development
    Clinical and Experimental Immunology (Q2, IF 3.4)
    📌 First Author
    🧫 Original Research

2024

  1. Neutrophil Heterogeneity in Hepatocellular Carcinoma and Tumor Immunity
    Cancer Medicine (Q2, IF 2.9)
    📌 Co-First Author
    🔬 Original Research

  2. Oxidative Balance in Diet and Sleep Patterns: A Metabolic Interaction
    Frontiers in Nutrition (Q2, IF 4.0)
    📌 Co-First Author
    🍽 Original Research

  3. CMTM4 Facilitates Gastric Cancer Metastasis via EMT Modulation
    Journal of Gastrointestinal Oncology (Q3, IF 2.0)
    📌 Co-First Author
    🧠 Original Research

  4. Cmtm4 Shapes Colitis Outcomes via Microbial Dysbiosis and Mucosal Immunity
    Journal of Genetics and Genomics (Q1, IF 6.6)
    📌 Co-Corresponding Author
    🧪 Original Research

  5. Serum Proteomics-Based Biomarkers of Precancerous Gastric Lesions
    Frontiers in Molecular Biosciences (Q2, IF 3.9)
    📌 Co-Corresponding Author
    🔍 Original Research

  6. Treg Subsets Orchestrate Tumor Microenvironment in Colorectal Cancer
    Frontiers in Immunology (Q1, IF 5.7)
    📌 Co-First & Corresponding Author
    🧫 Original Research

2023

  1. Helicobacter pylori and Inflammasome Activation in Gastric Pathogenesis (Review)
    Helicobacter (Q2, IF 4.3)
    📌 Co-Corresponding Author
    🧯 Review Article

2022

  • Lymphocyte Profile Alterations in Precancerous Gastric Lesions
    Journal of Leukocyte Biology (Q2, IF 5.5)
    📌 First Author
    🧬 Original Research

  • B7 Family Molecules and Immune Evasion in H. pylori Infection (Review)
    Helicobacter (Q2, IF 4.4)
    📌 Co-Corresponding Author
    🧫 Review Article

Conclusion

Dr. FU Weiwei demonstrates an exceptional and well-rounded profile as a medical researcher with significant contributions to immunology and gastroenterology, supported by prestigious academic training, a robust scientific publication record, impactful patents, and strong conference presence. These achievements, particularly in translational cancer immunology, make Dr. Fu highly suitable for the Best Researcher Award.

Alexander Shirokov | Molecular Biology | Best Researcher Award

Posted on by sciencefather

Dr. Alexander Shirokov | Molecular Biology | Best Researcher Award 

Senior Researcher at the Laboratory of Immunochemistry, at Ibppm ras, Russia.

Dr. Shirokov Alexander Alexandrovich, Ph.D., is an esteemed Associate Professor specializing in microbiology and immunochemistry. He serves as a Senior Researcher at the Laboratory of Immunochemistry and heads the Center for Collective Use “Symbiosis” at the Institute of Biochemistry and Physiology of Plants and Microorganisms (IBPPM) of the Russian Academy of Sciences. Additionally, he leads the Central Research Center at Saratov National Research State University. Dr. Shirokov’s research spans antigens, cell biology, and optical technologies, with a focus on glioblastoma and brain vascular systems. His extensive involvement in educational and public activities, including mentoring students and chairing scientific conferences, highlights his dedication to advancing scientific knowledge and nurturing young talent. Recognized for his contributions to science, Dr. Shirokov has received prestigious awards and continues to drive innovation in immunochemical and biotechnological research.

Profile

Scopus

ORCID

🎓 Education

Dr. Shirokov earned his Specialist degree in Organic and Bioorganic Chemistry from Saratov State University (1999–2004). He pursued postgraduate studies in Microbiology (specialty 03.02.03) at the Institute of Biochemistry and Physiology of Plants and Microorganisms, Russian Academy of Sciences (2004–2008), where he earned his Candidate of Biological Sciences (Ph.D.). His academic focus encompassed microbiology, biochemistry, and biotechnology. This solid educational foundation equipped him with expertise in immunochemistry, confocal microscopy, and cell biology. Dr. Shirokov’s teaching contributions include specialized courses on aerobiology and light microscopy. He has supervised numerous diploma projects and postgraduate theses, demonstrating a strong commitment to academic mentorship and research excellence.

👨‍💼 Experience

Dr. Shirokov has held multiple distinguished positions in academia and research. Since 2020, he has been a Senior Researcher at the Smart Sleep Laboratory and Head of the Central Research Center at Saratov National Research State University. Concurrently, he serves as a Senior Researcher and Center Head at IBPPM, focusing on immunochemistry and biotechnology. His leadership extends to mentoring students, managing diploma projects, and supervising postgraduate research. He has organized national scientific conferences and contributed to regional scientific councils, shaping policy and fostering young scientists. His career is marked by collaboration on high-impact projects in brain research, immunotherapy, and biotechnological innovation, enhancing our understanding of complex biological systems and their medical applications.

🔬 Research Interests 

Dr. Shirokov’s research spans immunochemistry, cell biology, and biotechnology. His primary focus areas include antigen characterization, glioblastoma research, and the vascular and lymphatic systems of the brain. Utilizing advanced techniques like confocal and electron microscopy, he explores cellular structures and immune responses. His work on brain immunology investigates innovative treatments for neurodegenerative diseases and brain tumors, such as photomodulation for Alzheimer’s therapy and glioblastoma suppression. Dr. Shirokov also delves into bionanotechnology, developing microencapsulation methods for targeted drug delivery. Keywords central to his research include cytology, histology, and optical technologies, reflecting a multidisciplinary approach to solving complex biomedical challenges.

🏆 Awards 

Dr. Shirokov has received several prestigious accolades. In 2010 and 2015, he was awarded certificates of honor by the Ministry of Industry and Energy of the Saratov Region for his scientific achievements. In 2013, he won the P.A. Stolypin Youth Prize, recognizing outstanding contributions to science by young researchers in the Saratov region. His leadership roles in scientific councils and conferences further underscore his recognition within the academic community. These awards highlight Dr. Shirokov’s dedication to advancing microbiology and immunochemistry, fostering innovation, and contributing to the scientific community’s growth. His efforts have not only elevated research standards but also inspired future generations of scientists.

📚Top Noted Publications 

Dr. Shirokov has published extensively in peer-reviewed journals, advancing knowledge in immunochemistry and neurobiology. Notable works include:

  • Shirokov, A., et al. (2024).
    Title: New insights into phototherapy of glioblastoma: the meningeal lymphatics and sleep.
    Journal: European Physical Journal Special Topics (Eur. Phys. J. Spec. Top.)
    Summary: This article explores the intersection of phototherapy for glioblastoma, emphasizing the role of meningeal lymphatic systems and sleep mechanisms. It suggests how targeted light-based therapies could improve outcomes by influencing these physiological pathways.
    Link: [Source not specified; can search based on title for access]
  • Shirokov, A., et al. (2023).
    Title: Optical modulation strategies for neurodegenerative diseases.
    Journal: Neuroscience Letters
    Impact: Cited by 15 articles as of the latest update.
    Summary: The study reviews advanced optical techniques, such as photobiomodulation, for treating neurodegenerative disorders like Alzheimer’s and Parkinson’s. It highlights mechanisms of action and potential clinical applications, suggesting how light therapies could modulate neuronal functions and disease progression.
    Link: [Similar to above; can locate via journal search]

Conclusion

Dr. Shirokov Alexander Alexandrovich presents a compelling case for the Best Researcher Award. His extensive research contributions, leadership in significant projects, and dedication to education position him as an outstanding candidate. With further emphasis on international collaboration and showcasing societal impact, his profile aligns well with the criteria for excellence in research and innovation.